Compare Intuitive Machines (LUNR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Machines vs Natera Inc. Common Stock — how do they compare? Intuitive Machines trades at $10.82 (market cap $1.97B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 28.9× Intuitive Machines's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Intuitive Machines nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Machines for 7 Days and Natera Inc. Common Stock for 0 Days on average.
| LUNR | NTRA | |
|---|---|---|
Market Cap | $1.97B | $57.03B |
Volume | 6,024,737 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $45.70 | $425.64 |
52-Week Low | $8.05 | $179.42 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $2.04B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Machines (LUNR) trades at $12.18, down 5.29% on the day, reflecting a bearish technical trend. The company is in a high-growth phase, with revenue projected to surge from $207 million in 2025 to $481 million in 2026, but it remains deeply unprofitable with a net loss margin of -27.1%. Recent news highlights its strategic position in lunar infrastructure and satellite manufacturing, supported by NASA contracts, though the stock faces pressure from broader sector weakness.
The investment case hinges on execution of its growth strategy amid significant cash burn. Analyst consensus is strongly bullish with an $31.33 price target, but high execution risk and persistent losses present a speculative opportunity. Key risks include dependence on government contracts and intense competition in the space sector.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Machines
Intuitive Machines provides lunar access, data, and infrastructure services. Its capabilities include lunar landers, communications systems, and technologies designed to support missions to the Moon.
Read more on LUNR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
